The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association

[1]  A. Sanyal,et al.  Modest alcohol consumption is associated with decreased prevalence of steatohepatitis in patients with non-alcoholic fatty liver disease (NAFLD). , 2012, Journal of hepatology.

[2]  N. Chalasani,et al.  Dyslipidemia in Patients with Nonalcoholic Fatty Liver Disease , 2012, Seminars in Liver Disease.

[3]  C. Lawton,et al.  Vitamin E and the Risk of Prostate Cancer: The Selenium and Vitamin E Cancer Prevention Trial (SELECT) , 2012 .

[4]  J. Lavine,et al.  Advances in pediatric nonalcoholic fatty liver disease. , 2011, Pediatric clinics of North America.

[5]  G. Musso,et al.  Meta-analysis: Natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity , 2011, Annals of medicine.

[6]  Giorgio Saracco,et al.  The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: An international collaborative study , 2011, Hepatology.

[7]  Michael Adler,et al.  Response-guided telaprevir combination treatment for hepatitis C virus infection. , 2011, The New England journal of medicine.

[8]  A. Baranova,et al.  Systematic review: the epidemiology and natural history of non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitis in adults , 2011, Alimentary pharmacology & therapeutics.

[9]  T. Kawaguchi,et al.  Meta‐analysis: insulin resistance and sustained virological response in hepatitis C , 2011, Alimentary pharmacology & therapeutics.

[10]  N. Chalasani,et al.  Endpoints and clinical trial design for nonalcoholic steatohepatitis , 2011, Hepatology.

[11]  B. Bacon,et al.  Diagnosis and Management of Hemochromatosis: 2011 Practice Guideline by the American Association for the Study of Liver Diseases , 2011, Hepatology.

[12]  Geoffrey Dusheiko,et al.  Telaprevir for previously untreated chronic hepatitis C virus infection. , 2011, The New England journal of medicine.

[13]  O. Weiland,et al.  Telaprevir for retreatment of HCV infection. , 2011, The New England journal of medicine.

[14]  V. de Lédinghen,et al.  A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis. , 2011, Journal of hepatology.

[15]  T. Saibara,et al.  Characteristics of patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma. , 2011, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[16]  P. Rosenthal,et al.  Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. , 2011, JAMA.

[17]  A. Craxì,et al.  Hepatic steatosis and insulin resistance are associated with severe fibrosis in patients with chronic hepatitis caused by HBV or HCV infection , 2011, Liver international : official journal of the International Association for the Study of the Liver.

[18]  Stefan Zeuzem,et al.  Boceprevir for previously treated chronic HCV genotype 1 infection. , 2011, The New England journal of medicine.

[19]  J. Bruix,et al.  Management of hepatocellular carcinoma: An update , 2011, Hepatology.

[20]  F. Ikeda,et al.  Alcohol consumption appears to protect against non‐alcoholic fatty liver disease , 2011, Alimentary pharmacology & therapeutics.

[21]  G. Bedogni,et al.  A combination of the pediatric NAFLD fibrosis index and enhanced liver fibrosis test identifies children with fibrosis. , 2011, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[22]  M. Budoff,et al.  Atorvastatin and Antioxidants for the Treatment of Nonalcoholic Fatty Liver Disease: The St Francis Heart Study Randomized Clinical Trial , 2011, The American Journal of Gastroenterology.

[23]  Niu Jun-q.  Interpretation:An update on treatment of genotype 1 chronic hepatitis C virus infection:2011 practice guideline by the American Association for the Study of Liver Diseases , 2011 .

[24]  D. Harnois.  The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: An international collaborative study , 2011 .

[25]  O. Cummings,et al.  Clinical significance of serum autoantibodies in patients with NAFLD: results from the nonalcoholic steatohepatitis clinical research network , 2011, Hepatology International.

[26]  Joel Z Stengel,et al.  Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. , 2011, Gastroenterology.

[27]  M. Manns,et al.  Boceprevir for untreated chronic HCV genotype 1 infection. , 2011, The New England journal of medicine.

[28]  D. Mikhailidis,et al.  Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis , 2010, The Lancet.

[29]  Enzo Bonora,et al.  Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. , 2010, The New England journal of medicine.

[30]  B. Neuschwander‐Tetri.  Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: The central role of nontriglyceride fatty acid metabolites , 2010, Hepatology.

[31]  C. Gluud,et al.  Meta‐analysis: antioxidant supplements for liver diseases – the Cochrane Hepato‐Biliary Group , 2010, Alimentary pharmacology & therapeutics.

[32]  T. Berg,et al.  High‐dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double‐blind, randomized, placebo‐controlled trial , 2010, Hepatology.

[33]  M. Stepanova,et al.  Components of metabolic syndrome are independent predictors of mortality in patients with chronic liver disease: a population-based study , 2010, Gut.

[34]  D. Reboussin,et al.  Effect of a 12-Month Intensive Lifestyle Intervention on Hepatic Steatosis in Adults With Type 2 Diabetes , 2010, Diabetes Care.

[35]  G. Musso,et al.  A meta‐analysis of randomized trials for the treatment of nonalcoholic fatty liver disease , 2010, Hepatology.

[36]  Rocio Lopez,et al.  The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis , 2010, Hepatology.

[37]  B. Neuschwander‐Tetri,et al.  Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. , 2010, The New England journal of medicine.

[38]  L. Terracciano,et al.  Oxidative stress and steatosis are cofactors of liver injury in primary biliary cirrhosis , 2010, Journal of Gastroenterology.

[39]  P. Hayes,et al.  Review article: omega-3 fatty acids - a promising novel therapy for non-alcoholic fatty liver disease. , 2010, Alimentary pharmacology & therapeutics.

[40]  K. Nouso,et al.  Nonalcoholic steatohepatitis-associated hepatocellular carcinoma: our case series and literature review. , 2010, World journal of gastroenterology.

[41]  K. Kowdley.  The role of iron in nonalcoholic fatty liver disease: the story continues. , 2010, Gastroenterology.

[42]  P. Giral,et al.  Long‐term efficacy of rosiglitazone in nonalcoholic steatohepatitis: Results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial , 2009, Hepatology.

[43]  Z. Chu,et al.  A 12‐Week Aerobic Exercise Program Reduces Hepatic Fat Accumulation and Insulin Resistance in Obese, Hispanic Adolescents , 2010, Obesity.

[44]  Greger Lindberg,et al.  Decreased survival of subjects with elevated liver function tests during a 28‐year follow‐up , 2010, Hepatology.

[45]  T. Barrientos-Gutiérrez,et al.  Bariatric surgery for non-alcoholic steatohepatitis in obese patients. , 2010, The Cochrane database of systematic reviews.

[46]  E. Jackvony,et al.  Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis , 2010, Hepatology.

[47]  U. Akarca,et al.  Efficacy of insulin-sensitizing agents in nonalcoholic fatty liver disease , 2010, European journal of gastroenterology & hepatology.

[48]  H. Huynh,et al.  AZD6244 enhances the anti-tumor activity of sorafenib in ectopic and orthotopic models of human hepatocellular carcinoma (HCC). , 2010, Journal of hepatology.

[49]  P. Hayes,et al.  Review article: omega‐3 fatty acids – a promising novel therapy for non‐alcoholic fatty liver disease , 2009, Alimentary pharmacology & therapeutics.

[50]  B. Velkeniers,et al.  IDENTIFYING NON-ALCOHOLIC FATTY LIVER DISEASE AMONG ASYMPTOMATIC OVERWEIGHT AND OBESE INDIVIDUALS BY CLINICAL AND BIOCHEMICAL CHARACTERISTICS , 2009, Acta clinica Belgica.

[51]  D. Torres,et al.  A Pilot Study Using Simvastatin in the Treatment of Nonalcoholic Steatohepatitis: A Randomized Placebo-controlled Trial , 2009, Journal of clinical gastroenterology.

[52]  F. Negro,et al.  Impact of obesity, steatosis and insulin resistance on progression and response to therapy of hepatitis C , 2009, Journal of viral hepatitis.

[53]  J. George,et al.  Aerobic exercise training reduces hepatic and visceral lipids in obese individuals without weight loss , 2009, Hepatology.

[54]  A. Feldstein,et al.  Nonalcoholic steatohepatitis in children: A multicenter clinicopathological study , 2009, Hepatology.

[55]  Hajime Sato,et al.  Light and Moderate Alcohol Consumption Significantly Reduces the Prevalence of Fatty Liver in the Japanese Male Population , 2009, The American Journal of Gastroenterology.

[56]  D. May,et al.  Effects of light-to-moderate alcohol consumption on steatosis and steatohepatitis in severely obese patients , 2009, European journal of gastroenterology & hepatology.

[57]  G. Kang,et al.  Clinical and Histological Features of Nonalcoholic Fatty Liver Disease in Children , 2009, Digestive Diseases and Sciences.

[58]  J. Newton,et al.  Non-Alcoholic Fatty Liver Disease in Older People , 2009, Gerontology.

[59]  Hong Tang,et al.  Prevalence and risk factors of fatty liver disease in Chengdu, Southwest China. , 2009, Hepatobiliary & pancreatic diseases international : HBPD INT.

[60]  M. Pencina,et al.  Vitamin E supplement use and the incidence of cardiovascular disease and all-cause mortality in the Framingham Heart Study: Does the underlying health status play a role? , 2009, Atherosclerosis.

[61]  F. Pattou,et al.  Prospective study of the long-term effects of bariatric surgery on liver injury in patients without advanced disease. , 2009, Gastroenterology.

[62]  J. Benson,et al.  The natural history of non-alcoholic fatty liver disease , 2006 .

[63]  J. Rotter,et al.  Correlates and Heritability of Nonalcoholic Fatty Liver Disease in a Minority Cohort , 2009, Obesity.

[64]  N. Schork,et al.  Heritability of nonalcoholic fatty liver disease. , 2009, Gastroenterology.

[65]  W. Coyle,et al.  The effect of metformin and standard therapy versus standard therapy alone in nondiabetic patients with insulin resistance and nonalcoholic steatohepatitis (NASH): a pilot trial , 2009, Therapeutic advances in gastroenterology.

[66]  D. Reeds,et al.  Dietary fat and carbohydrates differentially alter insulin sensitivity during caloric restriction. , 2009, Gastroenterology.

[67]  Xiao-yuan Xu,et al.  [Therapeutic and prevention strategies of gastroesophageal varices and variceal hemorrhage in cirrhosis]. , 2009, Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology.

[68]  Joshi,et al.  Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus. , 2009, The Journal of the Association of Physicians of India.

[69]  J. Gerss,et al.  The questionable association of vitamin E supplementation and mortality--inconsistent results of different meta-analytic approaches. , 2009, Cellular and molecular biology.

[70]  D. Berry,et al.  Bayesian model averaging in meta-analysis: vitamin E supplementation and mortality , 2009, Clinical trials.

[71]  Chunhong Bai,et al.  Long-term follow-up of patients with nonalcoholic fatty liver. , 2009, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[72]  Katsutoshi Tokushige,et al.  Clinical features and outcomes of cirrhosis due to non‐alcoholic steatohepatitis compared with cirrhosis caused by chronic hepatitis C , 2009, Journal of gastroenterology and hepatology.

[73]  B. McMahon,et al.  Chronic Liver Disease among Alaska-Native People, 2003–2004 , 2009, The American Journal of Gastroenterology.

[74]  Per Christoffersen,et al.  Final results of a long-term, clinical follow-up in fatty liver patients , 2009, Scandinavian journal of gastroenterology.

[75]  Raj Vuppalanchi,et al.  Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management , 2009, Hepatology.

[76]  K. Birkeland,et al.  Metformin in patients with non-alcoholic fatty liver disease: A randomized, controlled trial , 2009, Scandinavian journal of gastroenterology.

[77]  B. Neuschwander‐Tetri,et al.  Orlistat for overweight subjects with nonalcoholic steatohepatitis: A randomized, prospective trial , 2009, Hepatology.

[78]  J. Hoofnagle,et al.  Clinical trial: pilot study of metformin for the treatment of non‐alcoholic steatohepatitis , 2009, Alimentary pharmacology & therapeutics.

[79]  G. Salles,et al.  Prevalence and associated factors of non‐alcoholic fatty liver disease in patients with type‐2 diabetes mellitus , 2009, Liver international : official journal of the International Association for the Study of the Liver.

[80]  W. Rosenberg,et al.  Performance of ELF serum markers in predicting fibrosis stage in pediatric non-alcoholic fatty liver disease. , 2009, Gastroenterology.

[81]  T. Lehtimäki,et al.  Effect of weight loss on liver free fatty acid uptake and hepatic insulin resistance. , 2009, The Journal of clinical endocrinology and metabolism.

[82]  O. Gedik,et al.  The effect of metformin on leptin in obese patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease , 2009, Acta Diabetologica.

[83]  M. Taniai,et al.  Hepatocellular carcinoma in patients with nonalcoholic steatohepatitis , 2009, Journal of Gastroenterology.

[84]  F. Schick,et al.  High cardiorespiratory fitness is an independent predictor of the reduction in liver fat during a lifestyle intervention in non-alcoholic fatty liver disease , 2008, Gut.

[85]  M. V. Van Natta,et al.  Clinical correlates of histopathology in pediatric nonalcoholic steatohepatitis. , 2008, Gastroenterology.

[86]  K. Kasturi,et al.  Effect of bariatric surgery on nonalcoholic fatty liver disease: systematic review and meta-analysis. , 2008, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[87]  Z. Younossi,et al.  Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease. , 2008, Journal of hepatology.

[88]  Azmat Ali,et al.  Magnetic resonance imaging and spectroscopy for monitoring liver steatosis , 2008, Journal of magnetic resonance imaging : JMRI.

[89]  G. Aithal,et al.  Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. , 2008, Gastroenterology.

[90]  R. Xu,et al.  Suspected Nonalcoholic Fatty Liver Disease and Mortality Risk in a Population-Based Cohort Study , 2008, The American Journal of Gastroenterology.

[91]  B. Bell,et al.  Chronic Liver Disease Among Two American Indian Patient Populations in the Southwestern United States, 2000-2003 , 2008, Journal of clinical gastroenterology.

[92]  Philippe Giral,et al.  Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial. , 2008, Gastroenterology.

[93]  R. Idilman,et al.  Clinical trial: insulin‐sensitizing agents may reduce consequences of insulin resistance in individuals with non‐alcoholic steatohepatitis , 2008, Alimentary pharmacology & therapeutics.

[94]  M. Manco,et al.  Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease: A randomized, controlled trial , 2008, Hepatology.

[95]  J. Rood,et al.  Effect of 6‐Month Calorie Restriction and Exercise on Serum and Liver Lipids and Markers of Liver Function , 2008, Obesity.

[96]  R. Xu,et al.  Modest wine drinking and decreased prevalence of suspected nonalcoholic fatty liver disease , 2008, Hepatology.

[97]  G. Guyatt,et al.  GRADE: an emerging consensus on rating quality of evidence and strength of recommendations , 2008, BMJ : British Medical Journal.

[98]  J. Layden-Almer,et al.  Ethnicity and Nonalcoholic Fatty Liver Disease in an Obesity Clinic: The Impact of Triglycerides , 2008, Digestive Diseases and Sciences.

[99]  I. Guha,et al.  Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers , 2007, Hepatology.

[100]  P. Marcellin,et al.  Hepatic steatosis in chronic hepatitis C: baseline host and viral characteristics and influence on response to therapy with peginterferon α‐2a plus ribavirin , 2007, Journal of viral hepatitis.

[101]  Zhou-wen Chen,et al.  Relationship between alanine aminotransferase levels and metabolic syndrome in nonalcoholic fatty liver disease , 2008, Journal of Zhejiang University SCIENCE B.

[102]  S. Barlow,et al.  Expert committee recommendations regarding the prevention, assessment, and treatment of child and adolescent overweight and obesity: summary report. , 2007, Pediatrics.

[103]  James H. Lewis,et al.  Efficacy and safety of high‐dose pravastatin in hypercholesterolemic patients with well‐compensated chronic liver disease: Results of a prospective, randomized, double‐blind, placebo‐controlled, multicenter trial , 2007, Hepatology.

[104]  Y. Chawla,et al.  Metformin is effective in achieving biochemical response in patients with nonalcoholic fatty liver disease (NAFLD) not responding to lifestyle interventions. , 2007, Annals of hepatology.

[105]  A. Lincoff,et al.  Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. , 2007, JAMA.

[106]  Chien-Hua Chen,et al.  Prevalence and etiology of elevated serum alanine aminotransferase level in an adult population in Taiwan , 2007, Journal of gastroenterology and hepatology.

[107]  J. Sauver,et al.  Light to Moderate Alcohol Consumption Is Associated With Lower Frequency of Hypertransaminasemia , 2007, The American Journal of Gastroenterology.

[108]  A. Sanyal,et al.  Prevention and Management of Gastroesophageal Varices and Variceal Hemorrhage in Cirrhosis , 2007, The American Journal of Gastroenterology.

[109]  A. Feldstein,et al.  Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: Present and future , 2007, Hepatology.

[110]  E. Yu,et al.  Prevalence and risk factors of non-alcoholic fatty liver disease in potential living liver donors in Korea: a review of 589 consecutive liver biopsies in a single center. , 2007, Journal of hepatology.

[111]  F. Schick,et al.  Lifestyle intervention in individuals with normal versus impaired glucose tolerance , 2007, European journal of clinical investigation.

[112]  M. Holmqvist,et al.  Statins in non-alcoholic fatty liver disease and chronically elevated liver enzymes: a histopathological follow-up study. , 2007, Journal of hepatology.

[113]  D. Amarapurkar,et al.  Prevalence of non-alcoholic fatty liver disease: population based study. , 2007, Annals of hepatology.

[114]  R. Ersoy,et al.  Effects of vitamin E treatment on peroxisome proliferator‐activated receptor‐α expression and insulin resistance in patients with non‐alcoholic steatohepatitis: results of a pilot study , 2007 .

[115]  T. Therneau,et al.  The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD , 2007, Hepatology.

[116]  P. Puvanachandra,et al.  Hepatology outpatient service provision in secondary care: a study of liver disease incidence and resource costs. , 2007, Clinical medicine.

[117]  Christian Gluud,et al.  Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis. , 2007, JAMA.

[118]  F. Schick,et al.  High Visceral Fat Mass and High Liver Fat Are Associated with Resistance to Lifestyle Intervention , 2007, Obesity.

[119]  R. Ersoy,et al.  Effects of vitamin E treatment on peroxisome proliferator-activated receptor-alpha expression and insulin resistance in patients with non-alcoholic steatohepatitis: results of a pilot study. , 2007, Internal medicine journal.

[120]  D. Rockey,et al.  The Effect of a Low-Carbohydrate, Ketogenic Diet on Nonalcoholic Fatty Liver Disease: A Pilot Study , 2007, Digestive Diseases and Sciences.

[121]  Jimmy D Bell,et al.  Exercise training reduces fatty acid availability and improves the insulin sensitivity of glucose metabolism , 2006, Diabetologia.

[122]  J. Dufour,et al.  Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin e in nonalcoholic steatohepatitis. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[123]  J. Hardies,et al.  A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. , 2006, The New England journal of medicine.

[124]  H. Cortez‐Pinto,et al.  Hepatic histology in obese patients undergoing bariatric surgery. , 2006, Journal of hepatology.

[125]  Jeffrey B. Schwimmer,et al.  Prevalence of Fatty Liver in Children and Adolescents , 2006, Pediatrics.

[126]  M. Holmqvist,et al.  Long‐term follow‐up of patients with NAFLD and elevated liver enzymes , 2006, Hepatology.

[127]  H. Conjeevaram,et al.  Metabolic Syndrome Is Associated with Greater Histologic Severity, Higher Carbohydrate, and Lower Fat Diet in Patients with NAFLD , 2006, The American Journal of Gastroenterology.

[128]  Jimmy D Bell,et al.  Effect of nutritional counselling on hepatic, muscle and adipose tissue fat content and distribution in non-alcoholic fatty liver disease. , 2006, World journal of gastroenterology.

[129]  D. Nelson,et al.  Familial aggregation of insulin resistance in first-degree relatives of patients with nonalcoholic fatty liver disease. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[130]  P. Ciampalini,et al.  NAFLD in children: A prospective clinical‐pathological study and effect of lifestyle advice , 2006, Hepatology.

[131]  J. Browning.  Statins and hepatic steatosis: Perspectives from the Dallas Heart Study , 2006, Hepatology.

[132]  Lisa M Yerian,et al.  In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease , 2006, Hepatology.

[133]  J. Gisbert,et al.  A pilot study of atorvastatin treatment in dyslipemid, non‐alcoholic fatty liver patients , 2006, Alimentary pharmacology & therapeutics.

[134]  E. Ravussin,et al.  Effect of calorie restriction with or without exercise on insulin sensitivity, beta-cell function, fat cell size, and ectopic lipid in overweight subjects. , 2006, Diabetes care.

[135]  T. Asselah,et al.  Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. , 2006, Gastroenterology.

[136]  M. Leshno,et al.  Double-Blind Randomized Placebo-Controlled Trial of Orlistat or the Treatment of Nonalcoholic Fatty Liver Disease , 2022 .

[137]  A. Burroughs,et al.  Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study , 2006, Current medical research and opinion.

[138]  G. Bedogni,et al.  Prolonged n‐3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non‐alcoholic fatty liver disease: a pilot study , 2006, Alimentary pharmacology & therapeutics.

[139]  Robert A Fisher,et al.  Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C , 2006, Hepatology.

[140]  Y. Cho,et al.  Prevalence and risk factors of non‐alcoholic fatty liver disease among Korean adults , 2006, Journal of gastroenterology and hepatology.

[141]  G. Choudhuri,et al.  Effect of exercise and dietary modification on serum aminotransferase levels in patients with nonalcoholic steatohepatitis , 2006, Journal of gastroenterology and hepatology.

[142]  R. Krauss,et al.  Diagnosis and Management of the Metabolic Syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement , 2005, Current opinion in cardiology.

[143]  S. Kokkoris,et al.  Rosuvastatin as a novel treatment of non-alcoholic fatty liver disease in hyperlipidemic patients. , 2006, Atherosclerosis.

[144]  T. Omatsu,et al.  The Metabolic Syndrome as a Predictor of Nonalcoholic Fatty Liver Disease , 2006, Annals of Internal Medicine.

[145]  A. Suzuki,et al.  Effect of changes on body weight and lifestyle in nonalcoholic fatty liver disease. , 2005, Journal of hepatology.

[146]  P. Rosenthal,et al.  Underdiagnosis of pediatric obesity and underscreening for fatty liver disease and metabolic syndrome by pediatricians and pediatric subspecialists. , 2005, The Journal of pediatrics.

[147]  Fernando Costa,et al.  Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. , 2005, Circulation.

[148]  Hiroyuki Kaneda,et al.  The characteristics and natural history of Japanese patients with nonalcoholic fatty liver disease. , 2005, Hepatology research : the official journal of the Japan Society of Hepatology.

[149]  G. Tarantino,et al.  Non-Alcoholic Fatty Liver Disease in Young Adult Severely Obese Non-Diabetic Patients in South Italy , 2005, Annals of Nutrition and Metabolism.

[150]  C. Nievergelt,et al.  Histopathology of pediatric nonalcoholic fatty liver disease , 2005, Hepatology.

[151]  M. Arrese,et al.  Predictors of Nonalcoholic Steatohepatitis (NASH) in Obese Patients Undergoing Gastric Bypass , 2005, Obesity surgery.

[152]  E. Bugianesi,et al.  Steatosis and hepatocellular carcinoma risk. , 2005, European review for medical and pharmacological sciences.

[153]  S. Sanderson,et al.  The natural history of nonalcoholic fatty liver disease: a population-based cohort study. , 2005, Gastroenterology.

[154]  Y. Tamura,et al.  Effects of diet and exercise on muscle and liver intracellular lipid contents and insulin sensitivity in type 2 diabetic patients. , 2005, The Journal of clinical endocrinology and metabolism.

[155]  O. Cummings,et al.  Design and validation of a histological scoring system for nonalcoholic fatty liver disease , 2005, Hepatology.

[156]  A. Häkkinen,et al.  Dietary fat content modifies liver fat in overweight nondiabetic subjects. , 2005, The Journal of clinical endocrinology and metabolism.

[157]  G. Marchesini,et al.  A Randomized Controlled Trial of Metformin versus Vitamin E or Prescriptive Diet in Nonalcoholic Fatty Liver Disease , 2005, The American Journal of Gastroenterology.

[158]  H. Conjeevaram,et al.  One-Year Intense Nutritional Counseling Results in Histological Improvement in Patients with Nonalcoholic Steatohepatitis: A Pilot Study , 2005, The American Journal of Gastroenterology.

[159]  A. Jenkins,et al.  Associations between liver histology and severity of the metabolic syndrome in subjects with nonalcoholic fatty liver disease. , 2005, Diabetes care.

[160]  N. Chalasani.  Statins and hepatotoxicity: Focus on patients with fatty liver , 2005, Hepatology.

[161]  R. Andrade,et al.  Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. , 2005, Gastroenterology.

[162]  K. Petersen,et al.  Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes. , 2005, Diabetes.

[163]  N. Chalasani,et al.  Patients with Elevated Baseline Liver Enzymes Do Not Have Higher Frequency of Hepatotoxicity from Lovastatin than Those with Normal Baseline Liver Enzymes , 2005, The American journal of the medical sciences.

[164]  Roberto Pastor-Barriuso,et al.  Meta-Analysis: High-Dosage Vitamin E Supplementation May Increase All-Cause Mortality , 2005, Annals of Internal Medicine.

[165]  A. Suzuki,et al.  Chronological development of elevated aminotransferases in a nonalcoholic population , 2005, Hepatology.

[166]  J. Clore,et al.  A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis. , 2004, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[167]  Jonathan C. Cohen,et al.  Prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicity , 2004, Hepatology.

[168]  G. Farr,et al.  Metformin in the treatment of non‐alcoholic steatohepatitis: a pilot open label trial , 2004, Alimentary pharmacology & therapeutics.

[169]  Joe Kesterson,et al.  Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. , 2004, Gastroenterology.

[170]  P Christoffersen,et al.  Long term prognosis of fatty liver: risk of chronic liver disease and death , 2004, Gut.

[171]  S. Caldwell,et al.  The spectrum expanded: cryptogenic cirrhosis and the natural history of non-alcoholic fatty liver disease. , 2004, Journal of hepatology.

[172]  L. Burgart,et al.  Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: Results of a randomized trial , 2004, Hepatology.

[173]  A. Işık,et al.  Metformin in the treatment of patients with non‐alcoholic steatohepatitis , 2004, Alimentary pharmacology & therapeutics.

[174]  D. Purdie,et al.  Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life , 2004, Gut.

[175]  M. Saboorian,et al.  Ethnic Differences in the Prevalence of Cryptogenic Cirrhosis , 2004, American Journal of Gastroenterology.

[176]  K. Kaita,et al.  Fatty Infiltration of Liver in Hyperlipidemic Patients , 2000, Digestive Diseases and Sciences.

[177]  P. Hayashi,et al.  Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis , 2003, American Journal of Gastroenterology.

[178]  R. Koretz,et al.  Is weight reduction an effective therapy for nonalcoholic fatty liver? A systematic review. , 2003, The American journal of medicine.

[179]  D. Flum,et al.  Prevalence and predictors of asymptomatic liver disease in patients undergoing gastric bypass surgery. , 2003, Archives of surgery.

[180]  B. Neuschwander‐Tetri,et al.  Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR‐γ ligand rosiglitazone , 2003, Hepatology.

[181]  C. McClain,et al.  Cytokines and NASH: A pilot study of the effects of lifestyle modification and vitamin E , 2003, Hepatology.

[182]  James G Kench,et al.  Long‐term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C , 2003, Hepatology.

[183]  F. Brancati,et al.  The prevalence and etiology of elevated aminotransferase levels in the United States , 2003, American Journal of Gastroenterology.

[184]  G. Marchesini,et al.  Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome , 2003, Hepatology.

[185]  A. Häkkinen,et al.  Effects of identical weight loss on body composition and features of insulin resistance in obese women with high and low liver fat content. , 2003, Diabetes.

[186]  B. Neuschwander‐Tetri,et al.  Concurrence of Histologic Features of Steatohepatitis with Other Forms of Chronic Liver Disease , 2003, Modern Pathology.

[187]  Mauro Salizzoni,et al.  Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. , 2002, Gastroenterology.

[188]  D. Purdie,et al.  Effect of weight reduction on liver histology and biochemistry in patients with chronic hepatitis C , 2002, Gut.

[189]  W. Dietz,et al.  Management of child and adolescent obesity: summary and recommendations based on reports from pediatricians, pediatric nurse practitioners, and registered dietitians. , 2002, Pediatrics.

[190]  U. Visco-Comandini,et al.  Metformin in non-alcoholic steatohepatitis , 2002, The Lancet.

[191]  A. Terano,et al.  Plasma transforming growth factor‐β1 level and efficacy of α‐tocopherol in patients with non‐alcoholic steatohepatitis: a pilot study , 2001, Alimentary pharmacology & therapeutics.

[192]  Rahul Krishnarao Patil,et al.  Ninety patients with nonalcoholic steatohepatitis: insulin resistance, familial tendency, and severity of disease , 2001, American Journal of Gastroenterology.

[193]  J. Dixon,et al.  Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. , 2001, Gastroenterology.

[194]  A. Tavill.  Diagnosis and management of hemochromatosis , 2001, Hepatology.

[195]  O. Cummings,et al.  Atorvastatin for the treatment of NASH , 2001 .

[196]  A. Terano,et al.  Plasma transforming growth factor-beta1 level and efficacy of alpha-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study. , 2001, Alimentary pharmacology & therapeutics.

[197]  R. Fisher,et al.  Selection and outcome of living donors for adult to adult right lobe transplantation. , 2000, Transplantation.

[198]  S. Caldwell,et al.  Nonalcoholic steatohepatitis and cryptogenic cirrhosis within kindreds. , 2000, The American journal of medicine.

[199]  Z. Younossi,et al.  Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. , 1999, Gastroenterology.

[200]  K. Tanikawa,et al.  Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. , 1997, Journal of hepatology.

[201]  G. Gores,et al.  Ursodeoxycholic acid or clofibrate in the treatment of non‐alcohol‐induced steatohepatitis: A pilot study , 1996, Hepatology.

[202]  E. Shin,et al.  Effect of weight control on hepatic abnormalities in obese patients with fatty liver. , 1995, Journal of Korean medical science.

[203]  C. Gluud,et al.  Hepatic effects of dietary weight loss in morbidly obese subjects. , 1991, Journal of hepatology.

[204]  F. Schaffner,et al.  Effect of weight reduction on hepatic abnormalities in overweight patients. , 1990, Gastroenterology.